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Quality by Design (QbD) has been widely adopted by the pharmaceutical industry as a tool for transforming 
development, manufacture, and commercialization of drug products. QbD ensures that quality is built into a 
manufacturing process to consistently produce desired product. As per a FDA guidance1, QbD should be 
employed at the product development stage to ensure manufacture of a product with predefined quality. Here 
we present a retrospective QbD approach employed at Shire to define an improved control strategy for a 
commercial process using risk-based process understanding and characterization. Key challenges and 
considerations of implementing a QbD strategy on a commercial process are presented with examples of critical 
quality attribute review, parameter impact assessment, parameter classification review and updated control 
strategy. 
 
1US Food and Drug Administration. Guidance for industry: Q10 quality systems approach to pharmaceutical 
cGMP regulations (FDA, Rockville, MD, September 2006).   
 
